Free Trial
NASDAQ:ZYXI

Zynex Q3 2025 Earnings Report

Zynex logo
$1.48 +0.01 (+0.68%)
As of 11:01 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Zynex EPS Results

Actual EPS
N/A
Consensus EPS
-$0.19
Beat/Miss
N/A
One Year Ago EPS
N/A

Zynex Revenue Results

Actual Revenue
N/A
Expected Revenue
$22.71 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zynex Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, October 23, 2025
Conference Call Time
4:15PM ET

Conference Call Resources

Zynex Earnings Headlines

Reviewing Zynex (NASDAQ:ZYXI) & Resonate Blends (OTCMKTS:KOAN)
Trump’s new nightmare begins
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
Zynex announces new executive team
Zynex welcomes Steve Dyson as CEO, adds to leadership team
See More Zynex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zynex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zynex and other key companies, straight to your email.

About Zynex

Zynex (NASDAQ:ZYXI), Inc. is a medical device company engaged in the design, development, manufacture and sale of non-invasive therapeutic and patient monitoring equipment in the United States. Headquartered in Englewood, Colorado, the company focuses on delivering FDA-cleared solutions aimed at pain management, neurological rehabilitation and remote patient monitoring. Zynex’s portfolio is structured to address the needs of healthcare providers, outpatient clinics and patients receiving care in their homes.

The company’s core product offerings include electrotherapy devices—such as transcutaneous electrical nerve stimulation (TENS) and neuromuscular electrical stimulation (NMES) systems—designed to alleviate pain and assist in muscle recovery. Zynex also markets a range of soft goods, including bracing and support products, as well as disposable electrodes and accessories. In addition, the firm provides remote monitoring technologies that capture vital signs data, enabling clinicians to track patient health metrics outside of traditional care settings.

Zynex distributes its products primarily through a direct-to-provider sales model, supported by a field organization that spans multiple U.S. regions. The company works closely with hospitals, rehabilitation centers, home health agencies and durable medical equipment (DME) providers to integrate its therapies and monitoring systems into patient care protocols. By offering rental and purchase options, Zynex caters to a variety of reimbursement environments and patient needs.

Founded in 1996, Zynex has grown both organically and through selective acquisitions to expand its product lines and geographic reach. The company is led by Robert B. Rempel, who serves as President, Chief Executive Officer and Chairman of the Board, bringing decades of experience in healthcare innovation and corporate leadership. With a commitment to research, regulatory compliance and customer education, Zynex continues to pursue advances that enhance patient outcomes and support the evolving demands of modern healthcare delivery.

View Zynex Profile

More Earnings Resources from MarketBeat